肉瘤新药他泽司他在美国获批上市了吗？效果怎么样？

Tazerestat, an inhibitor of histone lysine methyltransferase EZH2, can inhibit the methylation of histone H3 lysine 27 (H3K27) and restore the expression of tumor suppressor genes. This drug is the first treatment plan specifically for epithelioid sarcoma. Today we will learn in detail whether the new sarcoma drug has been approved for marketing in the United States? What is the effect?

Tazerestat was developed by Epizyme. It was approved by the FDA for accelerated approval on January 23, 2020. The drug is indicated for the treatment of metastatic/locally advanced epithelioid sarcoma (ES) in adults and pediatric patients 16 years and older with metastatic/locally advanced epithelioid sarcoma who are not suitable for complete resection. Currently, the drug is not on the market in China. Patients can obtain tazerestat through Medical Companion Travel, which is cost-effective and can be directly mailed overseas to ensure that the drug is genuine. Tazerestat is the first and only approved EZH2 inhibitor.

So, what is the effect of the new sarcoma drug tazetostat?

In an open-label, single-arm cohort (Cohort 5) trial in the multicenter study (EZH-202, NCT02601950), all patients received tazerestat (800 mg twice daily) until the patient's disease progressed or an intolerable response occurred. The trial results showed that the ORR was 15%, the CR was 1.6%, and the proportion of patients with DOR ≥ 6 months was 67%. In another experiment, tazetostat treated patients with EZH2 mutant follicular lymphoma (FL), the response rate was about 65%, and the response duration was close to 1 year. The complete response rate is higher, about 12%; that's pretty good.

In order to ensure the therapeutic effect of tazerestat, patients should not change the dosage and usage at will during the medication. They should follow the doctor's instructions. If they have intolerance, they should contact the doctor in time and adopt a new treatment plan.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: